Bristol-Myers Squibb Company (BMY)
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive compensation while awaiting pipeline catalysts.
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus, reflecting pipeline strength. Shares trade at a discount to peers with a 14% FCF yield, while multiple late-stage drugs and recent acquisitions support long-term growth.
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield
Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug declines and supporting a raised 2025 revenue outlook of $47.5–$48.0 billion. Trading at less than 8x FCF and offering a 4.65% dividend yield, BMY appears undervalued relative to peers on key profitability metrics.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends
Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.
